-

Gilead Announces Racial Equity Community Impact Fund to Support Black Communities Across United States

Gilead Will Provide $10 Million in Grants to 20 Organizations in New 3-Year Program

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of its Racial Equity Community Impact Fund, which will support high-impact organizations working to tackle racial inequities affecting Black communities across the United States. The fund will initially provide $10 million in grants to 20 organizations over a three-year period.

The program will support organizations focused on three areas:

  • Community Advocacy and Mobilization: Groups that organize and mobilize communities to join the quest for racial equity and social justice, working toward an equitable distribution of resources for Black communities.
  • Social Justice: Organizations and historically Black colleges and universities (HBCUs) training the next generation of leaders.
  • Educational Innovation: Institutions focused on providing educational advancement and career development services for Black students, young professionals and families from cradle to career.

“Gilead is committed to creating equitable opportunities for the patients we serve, our employees and the communities in which we live and work,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “The Racial Equity Community Impact Fund will provide resources to groups that are working on the frontlines to combat social inequities directly impacting the health and wellness of the Black community. This program is one of the ways that we are delivering on our commitment to promote racial equity and social justice.”

The U.S.-based organizations that will receive funding include: 100 Black Men of Metropolitan Houston, Arkansas Regional Innovation Hub, Black Organizing for Leadership and Dignity (BOLD), Black Youth Project 100 (BYP100), Boys and Girls Clubs of Greater Washington, Center for Racial Justice in Education, Claflin University, East Oakland Youth Development Center, the Equity Alliance, Grantmakers for Girls of Color, Harlem Children’s Zone, Horatio Williams Foundation, the Marsha P. Johnson Institute, Morehouse College, Shaw University, Southerners on New Ground (SONG), Spelman College, Tougaloo College, Ubuntu Inc. and Xavier University of Louisiana.

“Gilead’s investment in the East Oakland Youth Development Center means 1,000 families will have access to capacity-building programs that will provide support to prepare youth and young adults for employment, higher education and leadership opportunities,” said Regina Jackson, President and Chief Executive Officer, East Oakland Youth Development Center. “These kinds of programs that provide trauma-informed care approaches are desperately needed in Oakland these days as we seek to combat social injustice and achieve racial equity for our community, one family at a time. We are grateful to Gilead for the support and partnership.”

The Racial Equity Community Impact Fund is among a number of programs implemented at Gilead in 2020 in the area of social justice. Gilead has also launched the Advancing Black Leadership Strategy, sponsored by the company’s executive leadership team, to deliver on internal inclusion and diversity goals, including increasing the number of Black employees hired and providing advancement opportunities for the company’s existing employees.

In July, the company announced a $1 million partnership with the Satcher Health Leadership Institute at the Morehouse School of Medicine to understand the impact of the COVID-19 pandemic on Black communities and to support the creation of a Black Health Equity Alliance composed of national thought leaders, community representatives, scholars, researchers and policymakers. This followed donations to the Entertainment Industry Foundation’s Know Your Rights Camp, Race Forward, the Equal Justice Initiative and Campaign Zero amid the violence against Black communities earlier this year.

Gilead’s social justice work also includes a number of initiatives aimed at promoting equity, particularly healthcare equity, for individuals in underserved communities. The company has committed more than $100 million over 10 years through the Gilead COMPASS Initiative® to community organizations in the Southern United States working to combat HIV/AIDS and in 2019 started the TRANScend® Community Impact Fund to support organizations committed to improving the safety, health and wellness of the transgender community.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contacts

Amy Flood, Media
(650) 522-5643

Gilead Sciences, Inc.

NASDAQ:GILD

Release Versions

Contacts

Amy Flood, Media
(650) 522-5643

More News From Gilead Sciences, Inc.

Gilead Foundation Commits Over $3 Million to Address Food Insecurity

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Foundation today announced that it has committed over $3 million in grants to expand access to food in communities across the United States. Gilead Foundation Healing Hunger awards will enable 14 regionally focused organizations to meet the unique needs of their communities by improving long-term nutrition access. The funding, distributed through the Gilead Foundation, supports organizations addressing food insecurity in California, North Carolina, N...

Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa

FOSTER CITY, Calif. & MBABANE, Eswatini--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead’s twice-yearly injectable HIV-1 capsid inhibitor – for the prevention of HIV as pre-exposure prophylaxis (PrEP) to Eswatini and Zambia. The deliveries advance ongoing efforts to accelerate equitable access to long-acting HIV prevention options across sub-Saharan Africa, which is home to approximately two-thirds of all people livin...

Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of adults with HIV who are virologically suppressed switching from a multi-tablet regimen to an investigational single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN). BIC/LEN efficacy was found to be statistically non-inferior to multi-tablet regimens. Gilead plans to file th...
Back to Newsroom